Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States at an offering price of $64.00 per ADS (the “Offering”).

Read more at globenewswire.com